Study of hormone refractory prostate cancer: Hospital care and palliative care resource use at a VA medical center

Cancer Investigation

Volumn 22, Issue 6, 2004, Pages 849-857

  Hwang, Shirley S ^a,b   Chang, Victor T ^a,c   Alejandro, Yvette ^a   Mulaparthi, Shalini ^a,c   Cogswell, Janet ^a   Srinivas, Shanti ^a,c   Kasimis, Basil ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Hormone refractory prostate cancer; Hospice; Hospitalization; Opioids; Palliative care; Survival

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; APPETITE STIMULANT; CORTICOSTEROID; DIURETIC AGENT; GONADORELIN ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LAXATIVE; MITOXANTRONE; MORPHINE; NEUROLEPTIC AGENT; OPIATE; PREDNISONE; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; BLOOD TRANSFUSION; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; CONFERENCE PAPER; HEALTH CARE QUALITY; HOSPICE CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HOSPICE CARE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 10844271622     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200039643     Document Type: Conference Paper

References (41)

1. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer statistics, 2001. CA Cancer. J. Clin. 2001, 51 (2), 15-36.
2. Knox, J.J.; Moore, M.J. Treatment of hormone refractory prostate cancer. Semin. Urol. Oncol. 2001, 19 (3), 202-211.
3. Kasimis, B.; Hwang, S.S.; Chang, V.T.; Srinivas, S.; Steafather, H.; Cogswell, J. Survival predictors in stage D3 prostate cancer in a cohort of VA patients: the role of the PSA doubling time. Proc. ASCO 2001, 20, 184a (abstract 732).
4. WHO Expert Committee Report. Cancerpain relief and palliative care. Technical Report Series No. 804; WHO: Geneva, 1990.
5. American Society of Clinical Oncology. Cancer care during the last phase of life. J. Clin. Oncol. 1998, 16 (5), 1986-1996.
6. Cherny, N.I.; Catane, R. Palliative medicine and the medical oncologist. Defining the purview of care. Hematol. Oncol. Clin. North Am. 1996, 10 (1), 1-20.
7. Maltoni, M.; Amadori, D. Palliative medicine and medical oncology. Ann. Oncol. 2001, 12 (4), 443-450.
8. Kasimis, B.; Hwang, S.S.; Chang, V.T.; Steafather, H.; Cogswell, J. Impact of intensive supportive care on the survival of patients with hormone resistant prostate cancer. Proc. ASCO 1998, 17, 61a (abstract 236).
9. Powell, I.J.; Banerjee, M.; Sakr, W.; Grignon, D.; Wood, D.P., Jr.; Novallo, M.; Pontes, E. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999, 85 (2), 472-477.
10. McLeod, D.G.; Schellhammer, P.F.; Vogelzang, N.J.; Soloway, M.S.; Sharifi, R.; Block, N.L.; Venner, P.M.; Patterson, A.L.; Sarosdy, M.F.; Kelley, R.P.; Kolvenbag, G.J. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate 1999, 40 (4), 218-224.
11. Fowler, J.E.; Bigler, S.A.; Renfroe, D.L.; Dabagia, M.D. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J. Urol. 1997, 158 (1), 150-154.
12. Optenberg, S.A.; Thompson, I.M.; Friedrichs, P.; Wojcik, B.; Stein, C.R.; Kramer, B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 1995, 274 (20), 1599-1605.
13. Kantoff, P.W.; Halabi, S.; Conaway, M.; Picus, J.; Kirshner, J.; Hars, V.; Trump, D.; Winer, E.P.; Vogelzang, N.J. Hydrocortsone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999, 17 (8), 2506-2513.
14. Tannock, I.F.; Osoba, D.; Stockler, M.R.; Ernst, D.S.; Neville, A.J.; Moore, M.J.; Armitage, G.R.; Wilson, J.J.; Venner, P.M.; Coppin, C.M.; Murphy, K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996, 14 (6), 1756-1764.
15. Smith, D.C.; Esper, P.; Strawderman, M.; Redman, B.; Pienta, K.J. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 1999, 17 (6), 1664-1671.
16. Tannock, I.F.; Osoba, D.; Stockler, M.R.; Ernst, D.S.; Neville, A.J.; Moore, M.J.; Armitage, G.R.; Wilson, J.J.; Venner, P.M.; Coppin, C.M.; Murphy, K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996, 14 (6), 1756-1764.
17. Christakis, N.A.; Iwashyna, T.J. Impact of individual and market factors on the timing of initiation of hospice terminal care. Med. Care. 2000, 38 (5), 528-541.
18. Stillman, M.J.; Syrjala, K.L. Differences in physician access patterns to hospice care. J. Pain Symptom Manage. 1999, 17 (3), 157-163.
19. Farnon, C.; Hofmann, M. Factors contributing to late hospice admission and proposals for change. Am. J. Hospice Palliat. Care 1997, 14 (5), 212-218.
20. Christakis, N.A. Timing of referral of terminally ill patients to an outpatient hospice. J. Gen. Intern. Med. 1994, 9 (6), 314-320.
21. Christakis, N.A. Predicting patient survival before and after hospice enrollment. Hosp. J. 1998, 13 (1-2), 71-87.
22. Rana, A.; Chisholm, G.D.; Rashwan, H.M.; Salim, A.; Merrick, M.V.; Elton, R.A. Symptomatology of metastatic prostate cancer: prognostic significance. Br. J. Urol. 1994, 73 (6), 683-686.
23. Vollmer, R.T.; Kantoff, P.W.; Dawson, N.A.; Vogelzang, N.J. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin. Cancer Res. 1999, 5 (4), 831-837.
24. Dowling, A.J.; Czaykowski, P.M.; Krahn, M.D.; Moore, M.J.; Tannock, I.F. Prostrate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J. Urol. 2000, 163 (5), 1481-1485.
25. Newling, D.; Fossa, S.D.; Andersson, L.; Abrahamsson, P.; Aso, Y.; Eisenberger, M.A.; Khoury, S.; Kozlowski, J.S.; Kelly, K.; Scher, H.; Hartley-Asp, B. Assessment of hormone refractory prostate cancer. Urology 1997, 49 (Suppl 4A), 46-53.
26. Catton, C.N.; Gospodarowicz, M.K. Palliative radiotherapy in prostate cancer. Semin. Urol. Oncol. 1997, 15 (1), 65-72.
27. Bruera, E.; Roca, E.; Cedaro, L.; Carraro, S.; Chacon, R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. 1985, 69 (7-8), 751-754.
28. Moertel, C.G.; Schutt, A.J.; Reitemeier, R.J.; Hahn, R.G. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974, 33 (6), 1607-1609.
29. Robustelli Della Cuna, G.; Pellegrini, A.; Piazzi, M. Effect of methylprednisolone sodium succinate on QOL in pre-terminal cancer patients: a placebo controlled, multi-center study. Eur. J. Cancer Clin. Oncol. 1989, 25 (12), 1817-1821.
30. Popiela, T.; Lucchi, R.; Giongo, F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur. J. Cancer Clin. Oncol. 1989, 25 (12), 1823-1829.
31. Storlie, J.A.; Buckner, J.C.; Wiseman, G.A.; Burch, P.A.; Hartmann, L.C.; Richardson, R.L. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostrate carcinoma. Cancer 1995, 76 (1), 96-100.
32. Sartor, O.; Weinberger, M.; Moore, A.; Li, A.; Figg, W.D. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998, 52 (2), 252-256.
33. Nishimura, K.; Nonomura, N.; Yasunaga, Y.; Takaha, N.; Inoue, H.; Sugao, H.; Yamaguchi, S.; Ukimura, O.; Miki, T.; Okuyama, A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000, 89 (12), 2570-2576.
34. Gleeson, C.; Spencer, D. Blood transfusion and its benefits in palliative care. Palliat. Med. 1995, 9 (4), 307-314.
35. Johansson, J.E.; Wersall, P.; Brandberg, Y.; Andersson, S.O.; Nordstrom, L.; EPO Study Group. Efficacy of Epoetin Beta on hemoglobin, quality of life and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. Scand. J. Urol. Nephrol. 2001, 35 (4), 288-294.
36. Sabbatini, P. The relationship between anemia and QOL in cancer patients. Oncologist 2000, 5 (1), 19-23.
37. Cleeland, C.S.; Demetri, G.D.; Glaspy, J.; Cella, D.F.; Portenoy, R.K.; Cremieux, P. Identifying hemoglobin level for optimal QOL: results of an incremental analysis. Proc. ASCO 1999, 18, 574a (Abstract 2215).
38. Derogatis, L.R.; Morrow, G.R.; Fetting, J.L.; Penman, D.; Piasetsky, S.; Schmale, A.M.; Henrichs, M.; Carnicke, C.L., Jr. The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249 (6), 751-757.
39. Roth, A.J.; Kornblith, A.B.; Batel-Copel, L.; Peabody, E.; Scher, H.I.; Holland, J.C. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 1998, 82 (10), 1904-1908.
40. Aus, G.; Hugosson, J.; Norlen, L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J. Urol. 1995, 154 (2 Pt 1), 466-469.
41. Axelsson, B.; Christensen, S.B. Medical care utilization by incurable cancer patients in a Swedish county. Eur. J. Surg. Oncol. 1997, 23 (2), 145-150.